Infectious complications of bispecific antibody therapy in patients with multiple myeloma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Infectious complications of bispecific antibody therapy in patients with multiple myeloma ; volume:13 ; number:1 ; day:10 ; month:3 ; year:2023 ; pages:1-4 ; date:12.2023
Blood cancer journal ; 13, Heft 1 (10.3.2023), 1-4, 12.2023
- Creator
-
Sim, Beatrice Z.
Longhitano, Anthony
Er, Jeremy
Harrison, Simon J.
Slavin, Monica A.
Teh, Benjamin W.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-023-00808-8
- URN
-
urn:nbn:de:101:1-2502270823318.021593798560
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sim, Beatrice Z.
- Longhitano, Anthony
- Er, Jeremy
- Harrison, Simon J.
- Slavin, Monica A.
- Teh, Benjamin W.
- SpringerLink (Online service)
Other Objects (12)
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Bispecific antibodies in the treatment of multiple myeloma
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
Improvement of pharmacokinetics of small recombinant bispecific antibody molecules
A human bispecific antibody neutralizes botulinum neurotoxin serotype A
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
Non-affinity platform for processing knob-into-hole bispecific antibody
Cell-type specific potent Wnt signaling blockade by bispecific antibody
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Bispecific antibodies in the treatment of multiple myeloma
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
Improvement of pharmacokinetics of small recombinant bispecific antibody molecules
A human bispecific antibody neutralizes botulinum neurotoxin serotype A
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
Non-affinity platform for processing knob-into-hole bispecific antibody
Cell-type specific potent Wnt signaling blockade by bispecific antibody
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Bispecific antibodies in the treatment of multiple myeloma
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
Improvement of pharmacokinetics of small recombinant bispecific antibody molecules
A human bispecific antibody neutralizes botulinum neurotoxin serotype A
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
Non-affinity platform for processing knob-into-hole bispecific antibody